TrialJournal for immunotherapy of cancer2025

Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB-D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915.

Georgina V Long et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.